Living with lung cancer that has spread to the liver is incredibly difficult. For patients with a specific type of lung cancer called driver gene-negative NSCLC, finding the right treatment path is vital. New data suggests that adding a PD-1 inhibitor—a type of immunotherapy—to standard chemotherapy can significantly improve outcomes compared to using chemotherapy alone.
The analysis looked at 20 different trials involving patients with this specific condition. The results showed that those who received both the immunotherapy and chemotherapy had better progression-free survival and overall survival rates. Specifically, a combination including Camrelizumab was ranked highly in these comparisons for both staying stable and extending life.
While these results are promising, it is important to remember that some of these findings come from indirect comparisons between different treatments. Because the data comes from a network analysis rather than direct head-to-head trials for every drug, doctors should view these results as a helpful guide rather than a definitive rule. Talk with your medical team to see if this combination is right for your specific situation.
